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Background: Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are one of the key components in highly
active anti-retroviral therapy because of their high specificity and less toxicity. NNRTIs inhibit reverse transcriptase
enzyme by binding to the allosteric site, which is 10Å away from the active site. Rapid emergence of resistance is
the major problem with all anti-HIV agents. Hence, there is continuous need to develop novel anti-HIV agents
active against both drug sensitive and resistance strains.
Results: All the 16 synthesized 2-(1,3-dioxo-3a,4-dihydro-1H-isoindol-2(3H,7H,7aH)-yl)-N-(substitutedphenyl)
acetamide 4(a-p) analogs were characterized by Fourier transform infrared spectroscopy, proton nuclear magnetic
resonance spectroscopy, mass spectroscopy, and elemental analysis. Lipinski rule of five parameters and molecular
parameters like solubility, drug likeness, and drug score were derived for designed analogs using online servers like
Molinspiration and Osiris property explorer. Synthesized compounds were evaluated for their HIV-1 reverse
transcriptase inhibitor activity by HIV-1 RNA-dependent DNA polymerase activity assay at 2 and 20 μM
concentrations.
Conclusions: Among the 16 synthesized compounds, 4a, 4b, 4f, 4g, 4k, and 4l showed weak reverse transcriptase
inhibitor activity at 20 μM concentration. For the designed compounds, there was no correlation observed between
molecular modeling and in vitro studies.
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TetrahydrophthalimideBackground
Acquired immune deficiency syndrome (AIDS) is the ad-
vance stage of infection caused by the human immunode-
ficiency virus (HIV-1). AIDS and AIDS-ailed infections are
major leading causes of death. According to UNAIDS-2012
report, 33 million people are living with AIDS and 1.7
million people died in the year 2011 [1]. Highly active anti-
retroviral therapy (HAART), a combination of two nucleo-
tide or nucleoside reverse transcriptase inhibitor (NRTIs)
and one protease inhibitor (PI), is generally used for AIDS.
Alternative combinations like two NRTIs and one non-
nucleoside reverse transcriptase inhibitor (NNRTI) or two
NRTIs and one integrase inhibitor are used. NNRTIs are* Correspondence: murugesaa789@gmail.com
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in any medium, provided the original work is pthe key components in HAART because of their high po-
tency, selectivity, and less toxicity when compared to
NRTIs and PIs [2,3]. Currently five NNRTIs are approved
by United States Food and Drug Administration. Among
them, nevirapine, delavirdine, and efavirenz are first
generation, which already got resistance. Etravirine and
rilpivirine are potent and currently using second gener-
ation NNRTIs. However, the occurrence of the high
mutation rate of the virus and the resulting emergence
of resistance make the researchers run a never-ending
marathon to keep developing new drugs active against
both drug-sensitive and drug-resistance strain with bet-
ter therapeutic profile [4,5].
Many NNRTIs, including tetrahydroimidazo [4,5,1-jkj]
[1,4] benzodiazepin-2(1H)-one and α-anilinophenyl aceta-
mide derivatives, adapt typical butterfly-like conformations
in non-nucleoside inhibitory binding pocket (NNIBP), withOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Figure 2 Structure of HIV-1 reverse transcriptase co-crystallized
with TNK-651 [14].
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and wing-2). Hydrophilic body contains mainly functional
groups like -NH, -C=O, and -OH which are able to form
hydrogen bonding interactions with active site amino acids
like K101, K103, and P236. Hydrophobic wings are π-elec-
tron containing aromatic ring system, which can form
hydrophobic interactions and pi-cationic interactions with
amino acids Y181, Y188, W229, F227, V106, P236, L100,
L234, and Y318 [6,7].
Compounds having phthalimide scaffold exhibit anti-
inflammatory [8], anticancer [9], antibacterial [10],
HIV-1 RT [11,12], and HIV-1 integrase inhibitory [13]
activities. An extensive perusal of literature revealed
that little work has been done on phthalimides and
tetrahydrophthalimide as NNRTIs. In view of these facts
and our interest on the development of novel NNRTIs,
we have chosen tetrahydrophthalimide scaffold as one of
the hydrophobic wings in butterfly-shape pharmacophore.
All the newly synthesized compounds were designed based
on the derived pharmacophoric model with acetamide moi-
ety as hydrophilic body, and tetrahydrophthalimide and
substituted aromatic amines as hydrophobic wings (general
structure shown in Figure 1).
Methods
Molecular docking study
The docking studies of all the derivatives 4(a-p) were
performed using molecular modeling software Autodock
4.2 (The Scripps Research Institute, CA, USA) [14] in-
stalled on a single machine running on a 3.4-GHz Pentium
processor with Windows XP SP2 as the operating system.
HIV-1 RT enzyme (pdb code 1rt2 (shown in Figure 2)) was
taken from the RCSB, used as target protein [7]. Target
protein pdb was further refined by removal of water mole-
cules and by adding polar hydrogens and Kollmancharges.
For the docking, a grid spacing of 0.375 Å and 63 × 63 ×
63 number of points were used. The grid was centered on
the active site. The auto grid program generated separateFigure 1 General structure of synthesized compounds.grid maps for all atom types of the ligand structures and
one for electrostatic interactions. PRODRG online server
was used to generate the energy minimized conformations
of the ligands in pdb format [15]. Energy minimized con-
formation of ligands was subjected to calculation of
Gasteiger-Huckel charges and saved in default format of
Autodock. Autodock generated 50 possible binding con-
formations, i.e., 50 runs for each docking by using LGA
search. Default protocol was applied, with initial popula-
tion of 150 randomly placed individuals, a maximum
number of 2.5 × 105 energy evaluations and 2.7 × 104 gen-
erations. A mutation rate of 0.02 and a crossover rate of
0.8 were used.
Validation of docking
Initially, the receptor was docked with extracted ligand
TNK 651 in order to validate the docking calculations,
reliability, and reproducibility of the docking parameters
for the study. It was evident that the docked pose of the
re-docked ligand was almost superimposed with that of
the co-crystallized ligand (Figure 3) with RMSD value of
0.5. Then, docking was performed with the standard
drug efavirenz with 1tr2 for validation, and the mode of
interaction was shown in Figure 4.
The binding free energies (docking score) and predicted
inhibitory constant (Ki) values of the designed analogs
were compared with binding free energies and inhibitory
constants of the co-crystallized ligand TNK-651 and stand-
ard drug efavirenz. Binding free energies and predicted
inhibitory constant values of TNK-651, efavirenz, and de-
signed analogs were given in Table 1. Docking studies of
Figure 3 Redocked mode of TNK 651 (3) (green) superimposed
with the co-crystallized ligand (gray). Ligand is shown as stick
model, and the amino acid residues interacting with the ligands are
shown as line model. Hydrogen bond interaction (1.9 Å) with LYS
103 amino acid residue of reverse transcriptase is shown as dotted
spheres. The rest of the protein is suppressed for
clarification purposes.
Table 1 Binding free energy and predicted inhibitory













2 TNK-651 - −11.88 1.95
3 4a H −8.13 1,100.0
4 4b 4-OCH3 −7.65 2,460.0
5 4c 4-CH3 −8.5 588.3
6 4d 4-Cl −7.79 1,930.0
7 4e 3-OCH3 −8.62 479.1
8 4f 3-CH3 −8.61 484.7
9 4g 3-Cl −8.87 315.7
10 4h 2-OCH3 −7.94 1,510.0
11 4i 2-CH3 −8.2 975.83
12 4j 2-Cl −8.2 975.83
13 4k 4-NO2 −10.53 19.11
14 4l 3-NO2 −10.89 10.38
15 4m 2-NO2 10.46 22.86
16 4n 2,4-diCH3 −8.87 313.63
17 4o 3,4-diCH3 10.49 20.37
18 4p 2-Cl, 3-CH3 −10.71 14.2
4k, 4l, 4m, 4o, and 4p showed satisfactory and comparable docking results as
that of standard drug efavirenz and TNK-651 (the same thing has been
discussed under the subsection “In vitro HIV-1 RT inhibitory activity” of the
“Results and discussion” section).
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Hydrophilic body of designed analogs showed hydrogen
bonding interactions with amino acids of receptor protein
1rt2. Hydrogen bonding interactions of compound 4l with
LYS 101 and LYS 103 are shown in Figure 5. All theFigure 4 Binding mode of standard drug efavirenz in the
NNIBP of HIV-1 RT (1rt2). Ligand is shown as stick model, and the
amino acid residues interacting with the ligands are shown as line
model. Hydrogen bond interactions (1.8 Å) with LYS 101 amino acid
residues of reverse transcriptase respectively are shown as dotted
spheres. The rest of the protein is suppressed for
clarification purposes.designed analogs showed similar orientation in NNIBP of
receptor protein. The orientation of some designed com-
pounds (having low binding free energy) in NNIBP of re-
ceptor is shown in Figure 6.
Molecular parameters
Lipinski rule of five parameters like ClogP, molecular
weight, number of hydrogen bond acceptors (HBA), num-
ber of hydrogen bond donors (HBD), solubility, drug like-
ness, and drug score were derived through online servers
Molinspiration (Molinspiration Cheminformatics, Nova
Ulica, Slovak Republic) and OSIRIS (Organic Chemistry,
Switzerland) property calculator [16,17]. All the calculated
values were given in Table 2.
Results and discussion
Chemistry
Designed analogs were synthesized using a synthetic proto-
col shown in Scheme 1. In the first step, 2-chloro-N-
(substituted phenyl) acetamide (2a-p) analogs were synthe
sized by treating substituted anilines with 2-chloroacetyl
chloride in dichloromethane and triethylamine as base. 2-
chloro-N-(substituted phenyl) acetamide (2a-p) intermedi-
ates were then treated with tetrahydrophthalimide (3)
Figure 5 Binding mode of compound 4l in the NNIBP of HIV-1
RT (1rt2). Ligand and the amino acid residues interacting with the
ligands are shown as ball-and-sticks model. Hydrogen bond
interactions (1.913 Å) with LYS 101 and (1.926 Å) with LYS 103 amino
acid residues of reverse transcriptase are shown as dotted spheres. The
rest of the protein is suppressed for clarification purposes.
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nitrile as solvent to yield titled compounds as final
products 4(a-p) [18,19].
Synthesized compounds were isolated as pure and
characterized by IR, 1H NMR, mass, and elemental ana-
lysis data. In general, the IR spectra of the synthesized
compounds showed N-H stretching at around 3,408 to
3,259 cm−1, C = O (amide) absorption band at around
1,703 to 1,682 cm−1, C = O (phthalimide) absorption
band at around 1,786 to 1,768 and 1,712 to 1,702 cm−1,
C-O-C absorption (methoxy) band at around 1,249 to
1,234 cm−1, and C-Cl absorption band at around 697 to
678 cm−1. The 1H NMR spectrum of the product 4c (see
‘Experimental’ section) showed two characteristicFigure 6 Overlay stereoview. 4k (pink), 4l (yellow), 4m (violet),
4o (red), and 4p (green)in the NNIBP of HIV-1 RT.singlets at δ 4.27 and δ 2.30 because of COCH2-N and
CH3, respectively. One broad singlet at δ 7.36 indicates
the presence of NH, two doublets at δ 7.32, and δ 7.10
confirms the presence of para-substituted benzene
ring. Besides these, the aliphatic region also showed the
characteristic multiplet peaks due to CH = CH, CH-
CH, and =CH-CH2 at δ 5.96 to 5.97, δ 3.21 to 3.23,δ
2.63 to 2.69, and δ 2.26 to 2.28, respectively. Mass
spectral analysis of the compounds4a and 4c showing
the molecular ion peak at 285.6 and 299.6 (M + 1), re-
spectively, confirms the molecular weight of the de-
sired compounds.
In vitro HIV-1 RT inhibitory activity
All the synthesized compounds 4(a-p) were evaluated
for HIV-1 RT inhibitory activity at concentrations 2 and
20 μM by using HIV-1 RT RNA-dependent DNA poly-
merase activity assay [20]. HIV-1 RT inhibitory activity
results are shown in Table 3. Rilpivirine was used as
standard drug in the assay.
Among the designed analogs, 4k, 4l, 4m, 4o, and 4p
showed satisfactory and comparable docking results such
as free binding energy and predicted inhibitory constant
(Ki) as that of standard drug efavirenz and TNK-651.
Docking results encourage us towards their synthesis and
in vitro RT inhibition evaluation. In vitro evaluation of
these compounds (4a, 4b, 4f, 4g, 4k, and 4l) showed weak
HIV-1 RT inhibitory activity at 20 μM concentration.
In this series of compounds 4a (2-(1,3-dioxo-3a,4-dihy-
dro-1H-isoindol-2(3H,7H,7aH)-yl)-N-phenylacetamide)
having un-substituted phenyl ring (mentioned as wing
2 in pharmacophore) showed 25% inhibition of HIV-1
RT at tested concentration of 20 μM. Compound 4f
(2-(1,3-dioxo-3a,4-dihydro-1H-isoindol-2(3H,7H,7aH)-yl)-
N-m-tolylacetamide), having m-tolyl (3-methylphenyl)
group as wing 2, inhibited 20% of HIV-1 RT at 20 μM con-
centration. However, none of these compounds showed
HIV-1 RT inhibition at 2 μM concentration.
Experimental
All solvents and reagents purchased from Sigma (Bangalore,
India) or Merck (NJ, USA) companies are used as received
without further purification. Solvent system used through-
out experimental work for running thin layer chromatog-
raphy was ethyl acetate and hexane mixture (30:70) in
order to monitor the reaction.
Melting points are uncorrected and were determined
in open capillary tubes on a Precision Buchi B530
(Flawil, Switzerland) melting point apparatus con-
taining silicon oil. IR spectra were recorded using a
Jasco FTIR spectrophotometer (JASCO, Inc., USA). 1H
NMR spectra were recorded on a Bruker DPX-400
spectrometer (Bruker India Scientific Pvt. Ltd., Mumbai)
using TMS as an internal standard (chemical shifts
Table 2 Predicted molecular parameters of the synthesized compounds
Compound code CLogP Molecular weight Number of HBA Number of HBD Solubility Drug likeness Drug score
4a 1.10 284 5 1 −2.45 2.29 0.7
4b 1.00 314 6 1 −2.47 2.67 0.34
4c 1.42 298 5 1 −2.79 2.54 0.42
4d 1.72 318 5 1 −3.19 4.71 0.69
4e 1.00 314 6 1 −2.47 3.65 0.43
4f 1.42 298 5 1 −2.79 3.56 0.71
4g 1.72 318 5 1 −3.19 3.93 0.69
4h 1.00 314 6 1 −2.47 4.05 0.72
4i 1.42 298 5 1 −2.79 4.07 0.71
4j 1.72 318 5 1 −3.19 4.17 0.55
4k 0.97 329 8 1 −2.91 −11.4 0.28
4l 0.97 329 8 1 −2.91 −1.34 0.27
4m 0.97 329 8 1 −2.91 −3.08 0.22
4n 1.74 312 5 1 −3.14 0.76 0.47
4o 1.74 312 5 1 −3.14 −0.22 0.32
4p 2.03 332 5 1 −3.53 3.93 0.66
Penta et al. Organic and Medicinal Chemistry Letters 2013, 3:8 Page 5 of 8
http://www.orgmedchemlett.com/content/3/1/8in δ). The ESMS were recorded on MICROMASS
Quattro-II LCMS system (Waters Corporation, Milford,
USA). Elemental analysis was performed on Vario EL III
M/s Elementar C, H, N, and S analyzer (Elementar
Analysensysteme GmbH, Germany).General procedure for synthesis of the compounds
3-(1,3-dioxo-3a,4-dihydro-1H-isoindol-2(3H,7H,7aH)-yl)-N-
(substituted phenyl) acetamides 4
To a solution of 3a,4,7,7a-tetrahydro-1H-isoindole-1,3
(2H)-dione (3) (2 mmol) in acetonitrile, potassium car-
bonate (6 mmol) and corresponding 2-chloro-N-(subs-
tituted phenyl) acetamides 2(a-p) (2 mmol) were added
and refluxed for 8 h. On completion of the reaction as










Scheme 1 Designed analogs synthesized using a synthetic protocol. (
(b) K2CO3, acetonitrile, reflux, 7 to 8 h.ice. Resulted precipitate was filtered, dried, and recrys-
tallized from ethanol to obtain pure product 4.2-(1,3-dioxo-3a,4-dihydro-1H-isoindol-2(3H,7H,7aH)-yl)-N-
phenylacetamide (4a)
White solid (yield 84%, MP = 96°C to 98°C). IR (KBr, cm−1):
3,271 (N-H), 1,776, and 1,712 (C = O, isoindole), 1,693 (C =
O, amide). MS (ES+): m/z = 285.6 [M + 1]. Analytically cal-
culated for C16H16N2O3 (%) C, 67.80; H, 5.25; N, 9.60.
Found: C, 67.75; H, 5.30; N, 9.55.2-(1,3-dioxo-3a,4-dihydro-1H-isoindol-2(3H,7H,7aH)-yl)-N-(4-
methoxyphenyl)acetamide (4b)
White solid (yield 92%, MP = 102°C to 104°C). IR (KBr,











a) Triethylamine, dichloromethane, room temperature, 30 min;







2 μM 20 μM
1 4a NA 25
2 4b NA 10
3 4c NA NA
4 4d NA NA
5 4e NA NA
6 4f NA 20
7 4g NA 15
8 4h NA NA
9 4i NA NA
10 4j NA NA
11 4k NA 15
12 4l NA 10
13 4m NA NA
14 4n NA NA
15 4o NA NA
16 4p NA NA
NA indicates not active.
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lated for C17H18N2O4 (%) C, 64.70; H, 5.55; N, 8.70.
Found: C, 64.75; H, 5.50; N, 8.65.
2-(1,3-dioxo-3a,4-dihydro-1H-isoindol-2(3H,7H,7aH)-yl)-N-p-
tolylacetamide (4c)
White solid (yield 82%, MP = 100°C to 102°C). IR (KBr,
cm−1): 3,408 (N-H), 1,772, and 1,712 (C = O, isoindole),
1,698 (C = O, amide). 1H NMR(400 MHz, CDCl3) 7.36
(brs, 1H, NH), 7.32 (d, J= 7.3 Hz, 2H, ArH), 7.10 (d, J=
7.1 Hz, 2H, ArH), 5.96 to 5.97 (m, 2H, CH = CH), 4.27
(s, 2H, CH2), 3.21 to 3.23 (m, 2H, CH-CH), 2.63 to 2.69
(m, 2H, CHH, CHH), 2.30 (s, 3H, CH3), 2.26 to 2.28 (m,
2H, CHH, CHH). MS (ES+): m/z = 299.6 [M + 1]. Ana-
lytically calculated for C17H18N2O3 (%) C, 68.60; H,
6.25; N, 9.70. Found: C, 68.65; H, 6.20; N, 9.65.
N-(4-chlorophenyl)-2-(1,3-dioxo-3a,4-dihydro-1H-isoindol-2
(3H,7H,7aH)-yl)acetamide (4d)
White solid (yield 84%, MP = 110°C to 112°C). IR (KBr,
cm−1): 3,363 (N-H), 1,768, and 1,706 (C = O, isoindole),
1,698 (C = O, amide), 689 (C-Cl). Analytically calculated
for C16H15ClN2O3 (%) C, 60.35; H, 4.60; N, 8.85. Found: C,
60.40; H, 4.55; N, 8.90.
2-(1,3-dioxo-3a,4-dihydro-1H-isoindol-2(3H,7H,7aH)-yl)-N-(3-
methoxyphenyl)acetamide (4e)
White solid (yield 78%, MP = 82°C to 84°C). IR (KBr, cm−1):
3,259 (N-H), 1,774, and 1,712 (C = O, isoindole), 1,703 (C =O, amide), 1,234 (C-O-C). Analytically calculated for
C17H18N2O4 (%) C, 64.80; H, 5.50; N, 8.65. Found: C, 64.75;
H, 5.55; N, 8.70.
2-(1,3-dioxo-3a,4-dihydro-1H-isoindol-2(3H,7H,7aH)-yl)-N-m-
tolylacetamide (4f)
White solid (yield 76%, MP = 86°C to 88°C). IR (KBr, cm−1):
3,342 (N-H), 1,776, and 1,712 (C = O, isoindole), 1,682 (C =
O, amide). Analytically calculated for C17H18N2O3 (%) C,
68.20; H, 6.35; N, 9.30. Found: C, 68.25; H, 6.30; N, 9.25.
N-(3-chlorophenyl)-2-(1,3-dioxo-3a,4-dihydro-1H-isoindol-2
(3H,7H,7aH)-yl)acetamide (4g)
White solid (yield 78%, MP = 92°C to 94°C). IR (KBr, cm−1):
3,290 (N-H), 1,768, and 1,712 (C = O, isoindole), 1,697 (C =
O, amide), 678 (C-Cl). Analytically calculated for C16
H15ClN2O3 (%) C, 60.50; H, 4.20; N, 8.90. Found: C, 60.45;
H, 4.15; N, 8.95.
2-(1,3-dioxo-3a,4-dihydro-1H-isoindol-2(3H,7H,7aH)-yl)-N-(2-
methoxyphenyl)acetamide (4h)
White solid (yield 76%, MP = 78°C to80°C). IR (KBr, cm−1):
3,345 (N-H), 1,774, and 1,712 (C = O, isoindole), 1,703 (C =
O, amide), 1,242(C-O-C). Analytically calculated for C17




White solid (yield 74%, MP = 92°C to 94°C). IR (KBr, cm−1).
3,265 (N-H), 1,772, and 1,705 (C = O, isoindole), 1,694 (C =
O, amide). Analytically calculated for C17H18N2O3 (%) C,
68.55; H, 6.25; N, 9.40. Found: C, 68.50; H, 6.30; N, 9.45.
N-(2-chlorophenyl)-2-(1,3-dioxo-3a,4-dihydro-1H-isoindol-2
(3H,7H,7aH)-yl)acetamide (4j)
White solid (yield 76%, MP = 88°C to 90°C). IR (KBr, cm−1):
3,302 (N-H), 1,784, and 1,702 (C = O, isoindole), 1,676 (C =
O, amide), 697 (C-Cl). Analytically calculated for C16
H15ClN2O3 (%) C, 60.10; H, 4.50; N, 8.95. Found: C, 60.15;
H, 4.45; N, 8.90.
2-(1,3-dioxo-3a,4-dihydro-1H-isoindol-2(3H,7H,7aH)-yl)-N-(4-
nitrophenyl)acetamide (4k)
Yellow solid (yield 86%, MP = 125°C to 127°C). IR (KBr,
cm−1): 3,325 (N-H), 1,779, and 1,710 (C = O, isoindole),
1,686 (C = O, amide), 1,542, 1,322 (C-NO2). Analytically
calculated for C16H15N3O5 (%) C, 58.60; H, 4.70; N,
12.55. Found: C, 58.55; H, 4.65; N, 12.60.
2-(1,3-dioxo-3a,4-dihydro-1H-isoindol-2(3H,7H,7aH)-yl)-N-(3-
nitrophenyl)acetamide (4l)
Yellow solid (yield 70%, MP = 112°C to 114°C). IR (KBr,
cm−1): 3,338 (N-H), 1,774, and 1,712 (C = O, isoindole),
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calculated for C16H15N3O5 (%) C, 58.45; H, 5.05; N,
12.45. Found: C, 58.50; H, 5.10; N, 12.50.
2-(1,3-dioxo-3a,4-dihydro-1H-isoindol-2(3H,7H,7aH)-yl)-N-(2-
nitrophenyl)acetamide (4m)
Yellow solid (yield 64%, MP = 102°C to 104°C). IR (KBr,
cm−1): 3,331 (N-H), 1,774, and 1,714 (C = O, isoindole),
1,698 (C = O, amide), 1,531, 1,336 (C-NO2). Analytically
calculated for C16H15N3O5 (%) C, 58.65; H, 4.80; N,
12.50. Found: C, 58.70; H, 4.85; N, 12.55.
N-(2,4-dimethylphenyl)-2-(1,3-dioxo-3a,4-dihydro-1H-
isoindol-2(3H,7H,7aH)-yl)acetamide (4n)
White solid (yield 86%, MP = 106°C to 108°C). IR (KBr,
cm−1): 3,284 (N-H), 1,782, and 1,712 (C = O, isoindole),
1,672 (C = O, amide). Analytically calculated for C18
H20N2O3 (%) C, 69.45; H, 6.60; N, 8.75. Found: C, 69.40;
H, 6.65; N, 8.70.
N-(3,4-dimethylphenyl)-2-(1,3-dioxo-3a,4-dihydro-1H-
isoindol-2(3H,7H,7aH)-yl)acetamide (4o)
White solid (yield 80%, MP = 110°C to 112°C). IR (KBr,
cm−1): 3,286 (N-H), 1,778, and 1,708 (C = O, isoindole),
1,697 (C = O, amide). Analytically calculated for
C18H20N2O3 (%) C, 69.65; H, 6.80; N, 8.60. Found: C,
69.60; H, 6.85; N, 8.65.
N-(2-chloro-3-methylphenyl)-2-(1,3-dioxo-3a,4-dihydro-1H-
isoindol-2(3H,7H,7aH)-yl)acetamide (4p)
White solid (yield 84%, MP = 118°C to 120°C). IR (KBr,
cm−1): 3,356 (N-H), 1,786, and 1,714 (C = O, isoindole),
1,695 (C = O, amide), 694 (C-Cl). Analytically calculated
for C17H17ClN2O3 (%) C, 61.50; H, 5.35; N, 8.65. Found:
C, 61.55; H, 5.40; N, 8.70.
HIV-1 RNA-dependent DNA polymerase activity assay
Poly(rA)/oligo(dT) was used as a template for the RNA-
dependent DNA polymerase reaction by HIV-1 RT, ei-
ther wild type or carrying the mutations. For the activity
assay, 25 μl final reaction volume contained TDB buffer
(50 mM Tris-HCl (pH 8.0), 1 mM dithiothreitol, 0.2 mg/
ml bovine serum albumin, 2% glycerol), 10 mM MgCl2,
0.5 mg of poly(rA)/oligo(dT)10:1 (0.3 mM 3′-OH ends),
and 10 mM 3[H]-dTTP (1 Ci/mmol), and was intro-
duced into tubes containing aliquots of different enzyme
concentrations (5 to 10 nM RT). After incubation at
37°C for indicated time, 20 μL from each reaction tube
were spiked on glass fiber filters GF/C and immediately
immersed in 5% ice-cold trichloroacetic acid (TCA)
(AppliChem GmbH, Darmstadt). Filters were washed
three times with 5% TCA and once with ethanol for 5
min, then dried, and finally added with EcoLume scintilla-
tion cocktail (ICN, Research Products Division, CostaMesa, CA, USA) to detect the acid precipitable radioactivity
by PerkinElmer Trilux MicroBeta 1450 Counter (Waltham,
MA, USA).
Conclusion
All the synthesized 3-(1,3-dioxo-3a,4-dihydro-1H-isoin-
dol-2(3H,7H,7aH)-yl)-N-(substituted phenyl) acetamide
4(a-p) analogs were evaluated for HIV-1 reverse tran-
scriptase inhibitor activity.
Among these synthesized compounds, 4a, 4b, 4f, 4g,
4k, and 4l showed weak HIV-1 RT inhibitor activity at
20 μM concentration. There was no correlation observed
between molecular modeling and in vitro studies for
these synthesized compounds.
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